News Quantified

BIO – bio-rad laboratories, inc. class a (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

Bio-Rad Laboratories (BIO) was downgraded by Citigroup Inc. from "buy" to "neutral". They now have a $300.00 price target on the stock.

???????????????????? : ????????????2035????834?8000??????????CAGR11.9%?????????·??????????? [CNET News]

Digital PCR Market Size to Hit USD 35.32 Billion by 2035, Fueled by Rising Cancer Prevalence and Precision Oncology Demand – SNS Insider [Yahoo! Finance]

Bio-Rad Laboratories, Inc. (BIO) Achieves Modest Revenue Growth and Robust Free Cash Flow Growth [Yahoo! Finance]

Bio-Rad Reports Fourth-Quarter and Full-Year 2025 Financial Results

-12.3%

MISS

-6.5%

MISS

17.6%

BEAT

-1.7%

BEAT

Form SCHEDULE 13G/A BIO-RAD LABORATORIES, Filed by: VANGUARD GROUP INC

Form ARS BIO-RAD LABORATORIES, For: Dec 31

Form DEF 14A BIO-RAD LABORATORIES, For: Apr 21

Form 8-K BIO-RAD LABORATORIES, For: Feb 19

Form 10-K BIO-RAD LABORATORIES, For: Dec 31

Top News Gainers

4/8 Biodesix Begins Coronavirus COVID-19 Testing 8.8%

3/12 Bio-Rad Announces that Through its Exact Diagnostics Product Line, the Company has Launched a SARS CoV-2 Standard for Coronavirus (COVID-19) Testing 8.7%

8/1 Form 8-K BIO-RAD LABORATORIES, For: Aug 01 8.3%

4/1 Form 3 BIO-RAD LABORATORIES, For: Apr 01 Filed by: RAMALINGAM AJIT 7.7%

2/13 Bio-Rad Reports Fourth-Quarter and Full-Year 2019 Financial Results 7.4%

10/31 Q3/2019 9/30/2019 EPS 1.610 ZacksConsensus 1.360 ActVsEst 0.250 - Beat 6.2%

5/8 Q1/2019 3/31/2019 EPS 1.650 ZacksConsensus 1.120 ActVsEst 0.530 - Beat 4.3%

3/2 Form 10-K BIO-RAD LABORATORIES, For: Dec 31 4.1%

12/13 Bio-Rad Makes Progress Recovering from Recent Ransomware Attack 3.5%

3/30 Bio-Rad Laboratories, Inc. (NYSE: BIO) had its price target lowered by analysts at Wells Fargo & Co from $440.00 to $385.00. They now have an "overweight" rating on the stock. 3.4%

Top News Decliners

3/20 Biodesix Partners with Bio-Rad to Bring Emergency Use Authorization (EUA) COVID-19 ddPCR™ Test to the U.S. -5.5%

8/2 Bio-Rad Laboratories, Inc. (NYSE: BIO) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. -5.1%

5/10 Form 10-Q BIO-RAD LABORATORIES, For: Mar 31 -4.8%

12/9 Form 8-K BIO-RAD LABORATORIES, For: Dec 05 -4.4%

9/9 Form 4 BIO-RAD LABORATORIES, For: Sep 05 Filed by: TUMOLO ANNETTE -3.7%

3/18 Bio-Rad Partners with Testing Labs Worldwide to Support COVID-19 Testing -3.4%

4/6 Form 8-K BIO-RAD LABORATORIES, For: Apr 01 -2.9%

4/9 Bio-Rad Acquires Celsee, Inc., a Single-Cell Analysis Solutions Provider -2.4%

4/21 Bio-Rad Begins Shipping SARS-COV-2 (COVID-19) Antibody Test That Offers More Than 99 Percent Specificity and 98 Percent Sensitivity -1.7%

9/20 Bio-Rad Laboratories, Inc. (NYSE: BIO) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. -1.6%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day